Citi raised the firm’s price target on Madrigal Pharmaceuticals to $389 from $382 and keeps a Buy rating on the shares after Rezdiffra was approved by the FDA as the first therapy to treat non-cirrhotic non-alcoholic steatohepatitis. No liver biopsies will be required for treatment, which Citi viewed as the biggest potential impediment to uptake, the analyst tells investor sin a research note. The firm believes Rezdiffra is well positioned for launch.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDGL:
- Madrigal Pharmaceuticals’ Rezdiffra™ Wins Accelerated FDA Approval
- Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
- Madrigal Pharmaceuticals price target raised to $405 from $275 at H.C. Wainwright
- Madrigal Pharmaceuticals price target raised to $338 from $336 at Canaccord
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
